Edgewise Therapeutics (EWTX) PT Lowered to $30 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EWTX Hot Sheet
Price: $37.53 -0.4%
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
JPMorgan analyst Tessa Romero lowered the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $30.00 (from $35.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
- Stanley Black & Decker (SWK) PT Raised to $135 at Jefferies
- Pfizer (PFE) PT Raised to $40 at Argus
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
